Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free AZN Stock Alerts

AstraZeneca (AZN) Competitors

AstraZeneca logo
£131.02 -112.00 (-0.85%)
As of 11:27 AM Eastern
Compare

AZN vs. GSK, ITH, SOPH, INDV, and HCM

Should you buy AstraZeneca stock or one of its competitors? MarketBeat compares AstraZeneca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AstraZeneca include GSK (GSK), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), Indivior (INDV), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

How does AstraZeneca compare to GSK?

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

GSK has a net margin of 17.78% compared to AstraZeneca's net margin of 17.19%. GSK's return on equity of 35.78% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.19% 22.41% 7.68%
GSK 17.78%35.78%9.56%

AstraZeneca has a beta of 0.223, indicating that its share price is 78% less volatile than the broader market. Comparatively, GSK has a beta of 0.298, indicating that its share price is 70% less volatile than the broader market.

In the previous week, GSK had 2 more articles in the media than AstraZeneca. MarketBeat recorded 8 mentions for GSK and 6 mentions for AstraZeneca. GSK's average media sentiment score of 0.18 beat AstraZeneca's score of -0.16 indicating that GSK is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
GSK
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£60.44B3.36£8.71B£664.0019.73
GSK£32.78B2.25£2.50B£142.1012.99

64.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 45.0% of GSK shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 0.2% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AstraZeneca currently has a consensus target price of £153.33, suggesting a potential upside of 17.03%. GSK has a consensus target price of GBX 2,034.29, suggesting a potential upside of 10.20%. Given AstraZeneca's stronger consensus rating and higher probable upside, equities analysts clearly believe AstraZeneca is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
GSK
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.4%. GSK pays an annual dividend of GBX 66 per share and has a dividend yield of 3.6%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. GSK pays out 46.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

AstraZeneca and GSK tied by winning 9 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Ithaca Energy?

AstraZeneca (LON:AZN) and Ithaca Energy (LON:ITH) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

AstraZeneca currently has a consensus target price of £153.33, suggesting a potential upside of 17.03%. Ithaca Energy has a consensus target price of GBX 205, suggesting a potential downside of 13.51%. Given AstraZeneca's higher possible upside, research analysts clearly believe AstraZeneca is more favorable than Ithaca Energy.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Ithaca Energy
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.4%. Ithaca Energy pays an annual dividend of GBX 30.31 per share and has a dividend yield of 12.8%. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Ithaca Energy pays out -594.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Ithaca Energy is clearly the better dividend stock, given its higher yield and lower payout ratio.

64.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 3.6% of Ithaca Energy shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 0.2% of Ithaca Energy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, AstraZeneca had 1 more articles in the media than Ithaca Energy. MarketBeat recorded 6 mentions for AstraZeneca and 5 mentions for Ithaca Energy. Ithaca Energy's average media sentiment score of 0.85 beat AstraZeneca's score of -0.16 indicating that Ithaca Energy is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AstraZeneca
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
Ithaca Energy
3 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AstraZeneca has a net margin of 17.19% compared to Ithaca Energy's net margin of 7.53%. AstraZeneca's return on equity of 22.41% beat Ithaca Energy's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.19% 22.41% 7.68%
Ithaca Energy 7.53%9.33%0.18%

AstraZeneca has higher revenue and earnings than Ithaca Energy. Ithaca Energy is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£60.44B3.36£8.71B£664.0019.73
Ithaca Energy£2.95B1.33£230.29M-£5.10N/A

AstraZeneca has a beta of 0.223, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Ithaca Energy has a beta of 0.353, suggesting that its stock price is 65% less volatile than the broader market.

Summary

AstraZeneca beats Ithaca Energy on 12 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Sophos Group plc (SOPH.L)?

AstraZeneca (LON:AZN) and Sophos Group plc (SOPH.L) (LON:SOPH) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

AstraZeneca has higher revenue and earnings than Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L) is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£60.44B3.36£8.71B£664.0019.73
Sophos Group plc (SOPH.L)£726.90M0.00N/A£1.70N/A

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.4%. Sophos Group plc (SOPH.L) pays an annual dividend of GBX 0.04 per share. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Sophos Group plc (SOPH.L) pays out 2.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, AstraZeneca had 6 more articles in the media than Sophos Group plc (SOPH.L). MarketBeat recorded 6 mentions for AstraZeneca and 0 mentions for Sophos Group plc (SOPH.L). Sophos Group plc (SOPH.L)'s average media sentiment score of 0.00 beat AstraZeneca's score of -0.16 indicating that Sophos Group plc (SOPH.L) is being referred to more favorably in the news media.

Company Overall Sentiment
AstraZeneca Neutral
Sophos Group plc (SOPH.L) Neutral

64.8% of AstraZeneca shares are held by institutional investors. 0.2% of AstraZeneca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AstraZeneca presently has a consensus target price of £153.33, suggesting a potential upside of 17.03%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts plainly believe AstraZeneca is more favorable than Sophos Group plc (SOPH.L).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Sophos Group plc (SOPH.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

AstraZeneca has a net margin of 17.19% compared to Sophos Group plc (SOPH.L)'s net margin of 0.00%. AstraZeneca's return on equity of 22.41% beat Sophos Group plc (SOPH.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.19% 22.41% 7.68%
Sophos Group plc (SOPH.L) N/A N/A N/A

Summary

AstraZeneca beats Sophos Group plc (SOPH.L) on 12 of the 15 factors compared between the two stocks.

How does AstraZeneca compare to Indivior?

Indivior (LON:INDV) and AstraZeneca (LON:AZN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, AstraZeneca had 5 more articles in the media than Indivior. MarketBeat recorded 6 mentions for AstraZeneca and 1 mentions for Indivior. Indivior's average media sentiment score of 0.67 beat AstraZeneca's score of -0.16 indicating that Indivior is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Indivior
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AstraZeneca
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Indivior has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.223, suggesting that its share price is 78% less volatile than the broader market.

86.0% of Indivior shares are owned by institutional investors. Comparatively, 64.8% of AstraZeneca shares are owned by institutional investors. 3.4% of Indivior shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AstraZeneca has a net margin of 17.19% compared to Indivior's net margin of 14.30%. AstraZeneca's return on equity of 22.41% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior14.30% -41.70% 2.37%
AstraZeneca 17.19%22.41%7.68%

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B1.38-£2.36M-£1.21N/A
AstraZeneca£60.44B3.36£8.71B£664.0019.73

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.4%. Indivior pays out -1,243.7% of its earnings in the form of a dividend. AstraZeneca pays out 47.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

AstraZeneca has a consensus price target of £153.33, indicating a potential upside of 17.03%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts plainly believe AstraZeneca is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
AstraZeneca
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

AstraZeneca beats Indivior on 14 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to HUTCHMED?

AstraZeneca (LON:AZN) and HUTCHMED (LON:HCM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

AstraZeneca has a beta of 0.223, meaning that its share price is 78% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.453, meaning that its share price is 55% less volatile than the broader market.

In the previous week, AstraZeneca had 6 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for AstraZeneca and 0 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.00 beat AstraZeneca's score of -0.16 indicating that HUTCHMED is being referred to more favorably in the news media.

Company Overall Sentiment
AstraZeneca Neutral
HUTCHMED Neutral

64.8% of AstraZeneca shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 0.2% of AstraZeneca shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HUTCHMED has a net margin of 104.77% compared to AstraZeneca's net margin of 17.19%. HUTCHMED's return on equity of 41.38% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
AstraZeneca17.19% 22.41% 7.68%
HUTCHMED 104.77%41.38%-5.90%

AstraZeneca currently has a consensus target price of £153.33, suggesting a potential upside of 17.03%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

AstraZeneca has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£60.44B3.36£8.71B£664.0019.73
HUTCHMED£548.51M2.73-£52.98M£53.003.28

Summary

AstraZeneca beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

Export
MetricAstraZenecaDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£203.19B£70.49B£6.25B£2.79B
Dividend Yield1.71%2.41%2.69%6.13%
P/E Ratio19.7325.0421.07364.76
Price / Sales3.36141.20556.3287,562.76
Price / Cash38.8916.1842.3127.85
Price / Book4.983.389.787.67
Net Income£8.71B£3.18B£3.56B£5.88B
7 Day Performance-6.31%-3.04%-0.18%6.53%
1 Month Performance-3.62%-6.28%4.95%9.76%
1 Year Performance23.16%13.45%28.44%75.45%

AstraZeneca Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
3.5064 of 5 stars		£131.02
-0.8%		£153.33
+17.0%		+25.0%£203.19B£60.44B19.7383,500
GSK
GSK
3.5866 of 5 stars		GBX 1,925
+0.5%		GBX 2,034.29
+5.7%		+20.0%£76.84B£32.78B13.5570,212
ITH
Ithaca Energy
1.6962 of 5 stars		GBX 237.45
-2.6%		GBX 205
-13.7%		+60.1%£3.92B£2.95BN/A220
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
INDV
Indivior
N/AGBX 1,238
+1.6%		N/A+33.9%£1.93B£1.40BN/A1,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AZN) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel